MEDRhythms Set to Begin Clinical Trial for Acute Stroke Survivors


MEDRhythms, a Portland based digital therapeutic company, announced today that it is launching a clinical trial that will study MR-010 acute stroke and asset.  The trial will be in partnership with U Massachusetts Memorial Healthcare and will examine the impact of MR-010 on acute stroke walking outcomes.

Stroke is the world’s top cause of long-term disability due to its high prevalence across the globe as well as its devastating health impacts.  Over a third of stroke survivors live in the US and according to the CDC, approximately 800,000 people in the US suffer a stroke annually.  Research shows that more than 80% of stroke survivors experience gait dysfunction.  MEDRhythms is dedicated to meeting the substantial unmet need by validating the efficacy of MR-010 in clinical trials.

This trial is funded by UMassachusetts and will be led by Dr. Brian Silver, Interim Chair in the Department of Neurology.  It will assess the feasibility of MR-010 to address working impairments in those in the acute phases of stroke.  The study will consist of two phases; the first phase will look at the impact of MR-010 within the acute hospital setting and the second phase will look at the continued impact of the therapeutic post-discharge.

“Given the prevalence and profound impact of walking deficits on stroke survivors, we are excited to be a part of investigating a promising new intervention in the acute stroke setting that could change the trajectory of rehabilitation for stroke patients,” said Dr. Brian Silver.

“We are honored to be collaborating with the nation’s leading researchers and institutions to build the evidence necessary to bring important care to all those who need it,” said Brian Harris, the CEO and co-founder of MEDRhythms.  “Strokes have devastating effects on mobility, which significantly impact independence and quality of life.  We look forward to making a positive impact on these patients throughout their entire recovery journey.”

MEDRhythms, a privately held company headquartered in Portland, is a digital therapeutics company that uses sensors, music and software to build evidence-based, neurologic interventions to measure survivors walking.